United Kingdom
United Kingdom

The 'go to' European specialist pharma company

Our commercial partners

Ruslan Akhmadov,
Head of Alliance Management,
Takeda Russia-CIS

'Norgine is well structured to support alliances. It has alliance management function, it has project management function, and it has good continuity and support from marketing and regulatory teams.'

Pier Vincenzo Colli,
General Manager,
Alfa Wassermann

'Norgine is very strong, it has good marketing and market access capabilities. This is exactly what we were looking for. A company which can successfully place our products.'
  Partner Details
Abeona Therapeutics

In August 2014, Norgine entered into a license agreement with PlasmaTech Biopharmaceuticals Inc. to develop and commercialise the medical device, MUGARD® in Europe for the prevention and management of the lesions and symptoms of oral mucositis. 


In October 2014, Norgine B.V signed expanded licensing agreement with PlasmaTech Biopharmaceuticals for MUGARD® to now include Australia and New Zealand.
Acino In June 2016, Norgine divested its MENA operations and products to Acino.
Alizyme Alizyme In 2009, Norgine acquired all rights to CAMETOR® (cetilistat) for obesity from Alizyme.
Alfa Wassermann Alfa Wassermann

In 2008, Norgine acquired the commercialisation rights from Alfa Wassermann for rifaximin-α for gastrointestinal indications such as traveller’s diarrhoea and hepatic encephalopathy.


Norgine currently holds marketing rights for XIFAXAN® 550mg (known as TARGAXAN® 550 in the UK and some other markets) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden, United Kingdom and Switzerland. Norgine and Alfa Wassermann co-promote the product under the TIXTAR® brand name in France.


Apharm s.r.l

In June 2015, Norgine entered an agreement with Apharm s.r.l. to distribute ZIVEREL® in Spain, Australia and New Zealand.

In 2016, Norgine extended its agreement with Apharm s.r.l to distribute ZIVEREL®  in addtional european countries. 

APR Applied Pharma Research (APR) In 2011, Norgine in-licensed SETOFILM® (Ondansetron RapidFilm® 4mg and 8mg) for chemotherapy and radiotherapy induced nausea and post-operative nausea in adults and children from Applied Pharma Research s.a. (APR). Norgine's rights cover Europe, Australia, New Zealand, South Africa, North Africa and the Middle East.
Aralez Pharmaceuticals In 2008, Norgine out licensed MOVIPREP® - bowel cleansing product, rights to Medical Futures (now Aralez) for Canada.
Arc Medical Design Limited.                                    

In March 2015, Norgine partnered with Arc Medical Design Ltd. for endoscopic device, ENDOCUFF VISION®.

In April 2015, Norgine acquires a 70% stake in Arc Medical Design Ltd. while retaining Arc Medical Design existing management, who will retain a 30% ownership stake.

ASPEN logo Aspen

On 30 Sept. 2015, Norgine B.V. completed its agreement with Pharmacare Limited, a wholly owned subsidiary of Aspen Pharmacare Holdings (collectively “Aspen”) for the divestment of its Southern African operations and product rights.

China Medical System Holdings Limited             In December 2014, Norgine partnered with China Medical System Holdings Limited for MOVICOL® in China.
Clinigen Group plc SpePharm AG, an affiliate of Norgine B.V sells SAVENE® (dexrazoxane) to Clinigen Group plc. March 2014.
Ajinomoto EA Pharma In 2008, Norgine out-licensed MOVIPREP® a bowel cleansing product, rights to EA Pharma for Japan.
Helsinn Helsinn In 1988, Norgine licensed-in KLEAN-PREP® - bowel cleansing product, from Helsinn.
Meda Meda Pharmaceuticals In 2012, Norgine divested over the counter products to Meda.
Modi-Mundipharma Modi-Mundipharma In 2010, Norgine out licensed MOVIPREP® - bowel cleansing product and MOVICOL® - constipation product, rights to Modi-Mundipharma for the Indian sub-continent.

Navidea Biopharmaceuticals Inc

In March 2015, Norgine and Navidea entered European partnership for LYMPHOSEEK®.
Image result for olympus corporation of americas Olympus Corporation of the Americas 

In May 2016, Norgine B.V. and its subsidiary Arc Medical Design Ltd entered into a new distribution agreement by which Arc appointed Olympus Corporation of the Americas as the exclusive distributor of ENDOCUFF VISION® in the US and Canada.


PharmaSwiss / Valeant PharmaSwiss / Valeant In 2008, Norgine out licensed MOVIPREP® rights to Valeant for CEE territories.
 Takeda Takeda In 2003, Takeda acquired the rights for development and commercialisation of CAMETOR® (cetilistat) known as OBLEAN® in Japan from Alizyme. The product is used to treat obesity. In 2009, all CAMETOR® rights were acquired by Norgine.

In 2011, Norgine out-licensed MOVIPREP® rights to Nycomed, now Takeda for Russia/CIS.

In 2005, Norgine out-licensed MOVIPREP® - bowel cleansing product, rights to Salix for the US.


In 2016, Norgine licensed NER1006 (PLENVU) to Valeant Pharmaceuticals for US and Canada.